Diagnostic management of suspected metastatic thyroid carcinoma: Clinical value of octreotide scintigraphy in patients with negative high-dose radioniodine scans

European Journal of Endocrinology

Volumn 150, Issue 3, 2004, Pages 277-283

  Giammarile, Francesco ^c   Houzard, Claire ^a   Bournaud, Claire ^b   Hafdi, Zakia ^a   Sassolas, Geneviève ^a   Borson Chazot, Fançoise ^a  

^a HÔPITAL NEUROLOGIQUE   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

^c CENTRE LÉON BÉRARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; PENTETREOTIDE IN 111; RADIOACTIVE IODINE; SOMATOSTATIN RECEPTOR; THYROGLOBULIN;

ADULT; AGED; ARTICLE; CANCER SCINTISCANNING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN TISSUE; INSULINOMA; MALE; MEDIASTINUM METASTASIS; METASTASIS; ONCOCYTOMA; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; TREATMENT PLANNING; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION;

ADULT; AGED; BIOPSY, FINE-NEEDLE; CARCINOMA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INDIUM RADIOISOTOPES; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; OCTREOTIDE; PROSPECTIVE STUDIES; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN; THYROID NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED; WHOLE-BODY COUNTING;

EID: 1842422426     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1500277     Document Type: Article

References (23)

1. Pineda JD, Lee T, Ain K, Reynolds JC & Robbins J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. Journal of Clinical Endocrinology and Metabolism 1995 80 1488-1492.
2. Maxon HR III & Smith HS. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinology and Metabolism Clinics of North America 1990 19 685-718.
3. Schlumberger MJ. Papillary and follicular thyroid carcinoma. New England Journal of Medicine 1998 338 297-306.
4. 131I-scintigraphy in the treatment and follow-up of thyroid cancer. Quarterly Journal of Nuclear Medicine 1999 43 195-206.
5. Burman KD, Anderson JH, Wartofsky L, Mong DP & Jelinek JJ. Management of patients with thyroid carcinoma: Application of thallium-201 scintigraphy and magnetic resonance imaging. Journal of Nuclear Medicine 1990 31 1958-1964.
6. Dadparvar S, Chevres A, Tulchinsky M, Krishna-Badrinath L, Khan AS & Slizofski WJ. Clinical utility of technetium-99m methoxisobutylisonitrile imaging in differentiated thyroid carcinoma: comparison with thallium-201 and iodine-131 Na scintigraphy, and serum thyroglobulin quantitation. European Journal of Nuclear Medicine 1995 22 1330-1338.
7. Grünwald F, Kalicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: Results of a multicentre study. European Journal of Nuclear Medicine 1999 26 1547-1552.
8. Helal BO, Merlet P, Toubert ME, Franc B, Schvartz C, Gauthier-Koelesnikov H et al. Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. Journal of Nuclear Medicine 2001 42 1464-1469.
9. Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausema L et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989 1 242-244.
10. Baudin E, Schlumberger M, Lumbroso J, Travagli JP, Caillou B & Parmentier C. Octreotide scintigraphy in patients with differentiated thyroid carcinoma: Contribution for patients with negative radioiodine scan. Journal of Clinical Endocrinology and Metabolism 1996 81 2541-2544.
11. Valli N, Catargi B, Ronci N, Leccia F, Guyot M, Roger P et al. Evaluation of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients with negative radioiodine scintigraphy. Thyroid 1999 9 583-589.
12. Garin E, Devillers A, Le Cloirec J, Bernard AM, Lescouarch J, Herry JY et al. Use of indium-111 pernetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients without detectable iodine uptake. European Journal of Nuclear Medicine 1998 25 687-694.
13. Sherman SI, Brierley JD, Sperling M, Ain KB, Bigos ST, Cooper DS et al. Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 1998 83 1012-1021.
14. Giammarile F, Hafdi Z, Bournaud C, Janier M, Houzard C, Desuzinges C et al. Is FDG PET useful in the management of suspected metastatic thyroid carcinoma in patients with no-detectable radioiodine uptake, European Journal of Endocrinology 2003 149 293-300.
15. Görges R, Kahaly G, Muller-Brand J, Macke H, Roser HW & Bockisch A. Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer. Thyroid 2001 11 647-659.
16. Postema PT, De Herder WW, Reubi JC, Oei HY, Kwekkeboom DJ, Bruining HJ et al. Somatostatin receptor scintigraphy in non-medullary thyroid cancer. Digestion 1996 57 36-37.
17. Ain KB, Taylor KD, Tofiq S & Venkataraman G. Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines. Journal of Clinical Endocrinology and Metabolism 1997 82 1857-1862.
18. Tisell LE, Ahlman H, Wangberg B, Kolby L, Fjalling M, Forssell-Aronsson E et al. Expression of somatostatin receptors in oncocytic (Hürthle cell) neoplasia of the thyroid. British Journal of Cancer 1999 79 1579-1582.
19. Joensuu H & Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. Journal of Nuclear Medicine 1987 28 910-914.
20. Feine U, Lietzenmayer R, Hanke JP, Held J, Wohrle H & Muller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. Journal of Nuclear Medicine 1996 37 1468-1472.
21. Lerch H, Schober O, Kuwert T & Saur HB. Survival of differentiated thyroid carcinoma studied in 500 patients. Journal of Clinical Oncology 1997 15 2067-2075.
22. Christian JA, Cook GJ & Harmer C. Indium-111-labelled octreotide scintigraphy in the diagnosis and management of non-iodine avid metastatic carcinoma of the thyroid. British Journal of Cancer 2003 89 258-261.
23. Stokkel MP, Reigman HI, Verkooijen RB & Smit JW. Indium-111-octreotide scintigraphy in differentiated thyroid carcinoma metastases that do not respond to treatment with high-dose I-131. Journal of Cancer Research and Clinical Oncology 2003 129 287-294.